Cipla gets into COVID-19 testing, with the launch of antibody test kits
The company has partnered with KARWA under the technology transfer from the Indian Council of Medical Research (ICMR).
Cyber attack that led to pause in worldwide operations was ransomware, investigation continues: Dr Reddy's
In a ransomware attack, the hackers breach the systems, install malware that encrypts a victim's files, then demand a ransom from the victim to restore access to the data.
The strange, listless response of Sun Pharma, India’s largest drugmaker, to Covid-19
Analysts and experts tracking the company told Moneycontrol that Sun Pharma has been measured in its Covid-19 response compared to some of its counterparts
Biocon Biologics bets on insulin glargine ramp-up as it looks overcome a tepid Q2
Despite the operational challenges posed by Covid-19, Biocon’s biologics division says it is committed to achieve its $1 billion revenue target by the end of FY22.
Coronavirus second wave: Lessons India can learn from Europe
The marked decrease in Covid-19 cases, is quite a contrast to the rising cases in Europe.
US approves Remdesivir for treating hospitalised Covid-19 patients
The agency concluded that Remdesivir demonstrated efficacy in treating hospitalized patients with Covid-19.
This startup is helping pharma cos go digital to promote drugs, including Remdesivir
Launched in March Doceree says it is already working with seven of the top 10 big pharmaceutical companies to rollout their brand promotion campaigns.
Siemens Healthineers to invest Rs 1,300 crore to set up new campus in Bengaluru
The new campus, to be opened in 2025, would be Siemens Healthineer's largest ever single investment made in India
COVID-19: Prices of RT-PCR test kits crash over 80%, but not many are happy
Increasing competition and price war see price of one kit dropping from Rs 1,200 in April to Rs 150 now. But quality of kits is the casualty. Early this month, Maharashtra returned 12.5 lakh RT-PCR test kits purchased from a private company, citing faulty results.
Russia's COVID-19 vaccine Sputnik V makes headway in India
Dr Reddy's gets the nod to conduct human trials for the vaccine while Mankind Pharma signs an agreement with RIDF that will make 300 million doses of Sputnik V available in India.
Explainer: What does WHO's Solidarity trial data mean for use of Remdesivir against Covid-19
Remdesivir had received regulatory approvals or temporary authorisations to treat COVID-19 in approximately 50 countries including India. The drug has been pre-qualified by WHO.
WHO Solidarity trial finds Remdesivir has no substantial effect on mortality in COVID-19 patients
The results of the Solidarity trial conducted on 11,266 hospitalised patients in 30 countries found remdesivir, along with three other repurposed drugs hydroxychloroquine, lopinavir/ritonavir and interferon to have little or no effect on 28-day mortality.
Apollo Hospitals ready to administer 1 million COVID-19 vaccines per day
Apollo Hospitals said it was training 10,000 healthcare workers to be able to administer the COVID-19 vaccine.
Bharat Biotech fast-tracks Covid-19 vaccine development; company cuts phase-2 size, will seek nod for phase-3
Instead of testing the vaccine candidate on 750 healthy volunteers in Phase-2, as approved for its clinical trial protocol, the company will now be testing it on just 380 volunteers. The 2019 Clinical Trial Rules require all protocol amendments to be submitted to the DCGI in writing along with the Ethics Committee’s letter of approval.
J&J's pause on late stage clinical trial of COVID-19 vaccine raises concerns
While serious adverse event are not uncommon in clinical trials, they raise concerns, especially when the vaccine development timelines are compressed, leaving less time to sufficiently analyse safety and efficacy of the drug or vaccine
Covid medicines help Cipla, Glenmark post strong sales growth in a subdued pharma market
The recovery was led by easing of lockdown restrictions and resumption of non-Covid related treatments.
USFDA inspections taking longer time than usual due to COVID-19 safety protocols
Sun Pharma, Auro Life, Lupin in the queue. Though generally, most inspections are done in a fortnight, now it’s taking almost a month. USFDA is taking precautions to ensure the safety of the investigators and the employees of the facility who assist its staff, say sources.
Mumbai blackout: Hospitals struggled to keep essential patient services running
As power is restored in most parts of the city, patients and hospital managements heave a sigh of relief.
Coronavirus vaccine: Bharat Biotech to use ViroVax's adjuvant for Covaxin
Bharat Biotech is currently conducting Phase II human trials of Covaxin after receiving approval from the Drug Controller General of India.
Pharma wrap: Festivals, winter perfect setting for Covid surge, can't afford to let the guard down
With a vaccine at least three months away, it becomes important for governments to manage the infection rates but it won't be easy.
Govt to launch behavioural change campaign to check COVID-19 spread
The government feels that there is a laxity in individual behaviour and is worried about upcoming winter and festival seasons, says NITI Aayog Member VK Paul.
COVID-19: Vaccine companies seek buying commitments from govt, global agencies to de-risk investment
Drug makers say it would help them plan better to create capacities. Three potential vaccines candidates from India -- Covishield of Serum Institute with license from AstraZeneca, Covaxin of Bharat Biotech, and ZyCov-D of Zydus Cadila -- have progressed into human trials phase.
COVID-19: Even as domestic demand for Remdesivir outstrips supply, manufacturers are exporting the drug
One drug company executive says as per the licensing agreement with Gilead, companies will have to cater to 127 countries. Gilead has signed deals with Cipla, Dr. Reddy's, Hetero Labs, Jubilant Life Sciences, Mylan, Syngene and Zydus Cadila.
Aster puts new hospital projects on hold, renegotiates lease agreements to tide over Covid crisis
Covid has impacted operations and the hospital chain expects normalcy to return only from the fourth quarter. CEO Harish Pillai, said Aster will focus on increasing capacity utilisation at existing projects and build a lab business in regions where it has a strong presence
- Business Insight | Tata Motors Q2 review: Passenger vehicle sales recover, commercial vehicle segment a concern Watch more
- Big Story | FM Sitharaman expects India to become one of the fastest-growing economies by FY22 Watch more
- LG Velvet launched in India with Snapdragon 845 chip, 48MP triple-camera, dual-screen combo Watch more
- Ideas For Profit | Polycab India is getting back on its feet, a good bet for the long haul Watch more